We are live on ! Find out more
Alyeska Investment Group

Alyeska Investment Group Portfolio holdings

AUM $35.4B
1-Year Est. Return 33.54%
This Fund
S&P 500
This Quarter Est. Return
+3.53%
1 Year Est. Return
+33.54%
3 Year Est. Return
+101.08%
5 Year Est. Return
+102.29%
10 Year Est. Return
+544.33%
AUM
$12B
AUM Growth
-$353M
Cap. Flow
-$617M
Cap. Flow %
-5.16%
Top 10 Hldgs %
12.46%
Holding
637
New
171
Increased
105
Reduced
150
Closed
191

Top Buys

Rank Stock Value
1
DAL icon
Delta Air Lines
DAL
+$140M
2
ABBV icon
AbbVie
ABBV
+$119M
3
KEY icon
KeyCorp
KEY
+$115M
4
FFIV icon
F5
FFIV
+$111M
5
WMT icon
Walmart Inc
WMT
+$110M

Top Sells

Rank Stock Value
1
ORCL icon
Oracle
ORCL
+$146M
2
SPGI icon
S&P Global
SPGI
+$142M
3
LLY icon
Eli Lilly
LLY
+$133M
4
LH icon
Labcorp
LH
+$131M
5
RHT
Red Hat Inc
RHT
+$121M

Sector Composition

Rank Sector Weight
1 Technology 17.86%
2 Healthcare 13.19%
3 Industrials 12.91%
4 Consumer Discretionary 10.27%
5 Financials 9.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TOVX icon
276
CALL
Theriva Biologics
TOVX
$10.3M
$5.66M 0.05%
1,143
– –
SNAK
277
DELISTED
Inventure Foods, Inc.
SNAK
$5.57M 0.05%
1,291,924
+15,272
+1% +$62.6K
JPM icon
278
JPMorgan Chase
JPM
$955B
$5.53M 0.05%
60,499
-155,132
-72% -$13.4M
ABR icon
279
Arbor Realty Trust
ABR
$965M
$5.47M 0.05%
+655,380
New +$5.52M
GOOS
280
Canada Goose Holdings
GOOS
$861M
$5.43M 0.05%
+275,000
New +$5.1M
FSTX
281
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$5.39M 0.05%
99,470
+61,380
+161% +$2.84M
SSYS icon
282
Stratasys
SSYS
$778M
$5.25M 0.04%
225,000
-1,122,889
-83% -$28.9M
GPMT
283
Granite Point Mortgage Trust
GPMT
$71.9M
$5.2M 0.04%
+275,000
New +$5.21M
CNCE
284
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$5.04M 0.04%
361,667
+159,595
+79% +$2.35M
DOC
285
DELISTED
PHYSICIANS REALTY TRUST
DOC
$5.04M 0.04%
250,000
-114,025
-31% -$2.31M
DD
286
DELISTED
Du Pont De Nemours E I
DD
$4.88M 0.04%
60,517
-573,800
-90% -$45.9M
CALD
287
DELISTED
Callidus Software, Inc.
CALD
$4.84M 0.04%
200,000
+50,000
+33% +$1.08M
CPAA
288
CALL
DELISTED
Conyers Park Acquisition Corp. Class A Common Stock
CPAA
$4.71M 0.04%
+400,000
New +$4.71M
SYNC
289
DELISTED
Synacor, Inc.
SYNC
$4.69M 0.04%
+1,284,431
New +$4.56M
ZNGA
290
DELISTED
ZYNGA INC. CL A COMMON
ZNGA
$4.67M 0.04%
1,284,388
-9,720,325
-88% -$31.9M
SNDX icon
291
Syndax Pharmaceuticals
SNDX
$1.77B
$4.54M 0.04%
325,000
+152,614
+89% +$1.74M
GNTX icon
292
Gentex
GNTX
$5.14B
$4.36M 0.04%
229,773
-108,234
-32% -$2.11M
KREF
293
KKR Real Estate Finance Trust
KREF
$464M
$4.3M 0.04%
+200,000
New +$4.39M
MSCI icon
294
MSCI
MSCI
$41.6B
$4.22M 0.04%
41,017
+1,017
+3% +$102K
AUPH icon
295
Aurinia Pharmaceuticals
AUPH
$1.95B
$4.1M 0.03%
669,346
-120,846
-15% -$814K
SPWH icon
296
Sportsman's Warehouse
SPWH
$46M
$4.05M 0.03%
750,000
-191,450
-20% -$964K
LOXO
297
DELISTED
Loxo Oncology, Inc
LOXO
$4.01M 0.03%
+50,000
New +$2.77M
HSIC icon
298
Henry Schein
HSIC
$10.2B
$4.01M 0.03%
+55,840
New +$3.89M
CBIO
299
Crescent Biopharma
CBIO
$586M
$3.91M 0.03%
+3,500
New +$2.89M
NGNE icon
300
Neurogene
NGNE
$718M
$3.9M 0.03%
13,876
+6,568
+90% +$1.88M
10 11
12
13 14

Similar funds

Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
SAM
Storebrand Asset Management Lysaker, Norway $34.8B AUM 25.49% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return
MML Investors Services
MML Investors Services Springfield, Massachusetts $36.1B AUM 19.68% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
VIA
Vanguard Investments Australia Victoria, Australia $34.6B AUM

Alyeska Investment Group's Q2 2017 Portfolio in Review

As of Q2 2017, Alyeska Investment Group held 637 positions worth $12B, down 2.9% from $12.3B the previous quarter. Its ten largest holdings account for 12% of the portfolio.

Alyeska Investment Group withdrew a net $617M in Q2 2017, closing 191 positions and reducing 150 holdings. Its most notable exit was Eli Lilly, an estimated $133M position sold in full.

By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 14% a quarter earlier, followed by Healthcare and Industrials.

Against the trend, Alyeska Investment Group opened a new position in AbbVie worth $128M.

  • Alyeska Investment Group's largest Q2 2017 buy was AbbVie: 1,771,895 shares worth $128M.
  • Alyeska Investment Group added most to Delta Air Lines in Q2 2017, an estimated $140M increase.
  • Alyeska Investment Group's biggest Q2 2017 reduction was Oracle, cutting an estimated $146M.
  • Alyeska Investment Group fully exited Eli Lilly in Q2 2017, selling an estimated $133M.
  • Alyeska Investment Group's ten largest holdings make up 12% of its $12B portfolio in Q2 2017.
  • Alyeska Investment Group opened 171 new positions and closed 191 in Q2 2017.
  • Alyeska Investment Group's portfolio value fell 2.9% quarter-over-quarter to $12B.

Based on Alyeska Investment Group's 13F filing for Q2 2017, filed 14 Aug 2017.